Targeting the Incretin Pathways in Type 2 Diabetes

Ralph A. DeFronzo, MD, discusses the utilization of glucagon-like peptide-1 (GLP-1) agonists and incorporating evidence-based guidelines into practice when considering the use of incretin-based therapies for type 2 diabetes.

For mFor more videos, visit our partners at The Doctor's Channel.

Submit Feedback